For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.
|13/03/2013||16/04/2013||Full Pharmacoeconomic Evaluation Recommended.|
|26/09/2013||30/12/2013||Reimbursement not recommended at the submitted price|
The HSE has approved reimbursement following confidential price negotiations.
|The HSE has now requested a full HTA for this product 25th June 2018|
|Full pharmacoeconomic assessment commissioned by HSE||25/06/2018|
|Pre-submission consultation with Applicant||05/07/2018|
|Submission received from Applicant||10/09/2018|
|Preliminary review sent to Applicant||05/12/2018|
|NCPE assessment re-commenced||14/01/2019|
|Preliminary review II sent to Applicant||30/01/2019|
|NCPE assessment re-commenced||15/02/2019|
|Factual accuracy sent to Applicant||19/03/2019|
|NCPE assessment re-commenced||02/04/2019|
|Current status||NCPE assessment ongoing|